ABBV-RGX-314 : REGENXBIO reports positive Phase 2 data on diabetic retinopathy gene therapy candidate
REGENXBIO Inc. has disclosed new findings from its Phase II ALTITUDE trial, focusing on ABBV-RGX-314 as a gene therapy for diabetic retinopathy (DR) treatment. This announcement comes ahead of a detailed presentation set for the American Academy of Ophthalmology meeting by Dr. Mark Barakat of Retinal Consultants of Arizona. ALTITUDE Trial and Diabetic Retinopathy: The […]